TON - October 2011 Vol 4 No 7

TON - October 2011 Vol 4 No 7 published on October 19, 2011 in Cancer Center Profile

The Cleveland Clinic was founded in 1921 in Cleveland, Ohio, by 4 physicians. At that time, it was one of the few group practices in the United States. This group practice model was very familiar to 3 of the founders—George Crile Sr, Frank Bunts, William Lower—as they served together in military hospitals near the front lines in World War I. These 3 colleagues were determined to establish a not-for-profit clinic that combined the best of military and civilian medical practices.

SAN FRANCISCO—A number of interventions can help reduce breast cancer among women at high risk, but uptake is sluggish, and there can be confusion about which agent to prescribe to a given patient. Seema Khan, MD, professor of surgery at Northwestern University Feinberg School of Medicine, Chicago, addressed the topic of pharmacologic risk reduction at the 2011 Breast Cancer Symposium.

TON - October 2011 Vol 4 No 7 published on October 19, 2011 in Navigation

SAN ANTONIO—More than 300 oncology nurse and patient navigators discussed the advancement of their profession at the Second Annual Navigation and Survivorship Conference, a forum for navigators to connect with one another and discuss the changing landscape of patient navigation and survivorship care for patients with cancer. “Ultimately, the networking of these professionals is so important to patient care, because it enables a forum for the sharing of ideas and experiences to impact practice,” said Sean T.

TON - October 2011 Vol 4 No 7 published on October 19, 2011 in FDA News & Updates

The US Food and Drug Administration (FDA) has approved denosumab (Prolia, Amgen) to increase bone mass in patients at high risk for fracture receiving androgen-deprivation therapy for nonmetastatic prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.

TON - October 2011 Vol 4 No 7 published on October 19, 2011 in FDA News & Updates

The FDA has granted 510k marketing clearance to an invitro diagnostic assay (NADiA ProsVue, Iris International) for determining rate of change of serum total prostate-specific antigen over a period of time. A slope of 3 assays is indicated for use as a prognostic marker in conjunction with clinical evaluation to aid in identifying those patients at reduced risk for recurrence of prostate cancer for the 8-year period following prostatectomy.

TON - October 2011 Vol 4 No 7 published on October 19, 2011 in FDA News & Updates

The FDA issued a statement warning physicians of changes in the package insert for bevacizumab (Avastin, Genentech) regarding newly identified risks.

TON - October 2011 Vol 4 No 7 published on October 19, 2011 in In the News

Thanks to medical research, there are nearly 12 million cancer survivors living in the United States today. And the research continues: There are approximately 400 new cancer therapies in preclinical and clinical development. As progress continues to treat those with cancer, let’s examine the statistics related to clinical trial participation.


From 1996 through 2002, National Cancer Institute (NCI)-sponsored cooperative group nonsurgical treatment trials for breast, colorectal, lung, and prostate cancers enrolled 75,215 patients:

TON - October 2011 Vol 4 No 7 published on October 19, 2011 in Hematologic Cancers

CHICAGO—Treatments for multiple myeloma have advanced rapidly over the past 15 years as research has fostered an improved understanding of the mechanisms of the disease. These discoveries have been translated into effective drugs, most notably bortezomib, thalidomide, and lenalidomide.

TON - October 2011 Vol 4 No 7 published on October 19, 2011 in Pharmacoeconomics

For antiemetic prophylaxis, a model of shared cost-savings using incentives such as cash rebates might reduce the high cost of some pharmaceuticals while maintaining patient access to optimal care, according to oncologists from Michigan.

TON - October 2011 Vol 4 No 7 published on October 19, 2011 in Best Practices

Many oncology nurses may be wearing uniforms that contain harmful bacteria, including drug-resistant organisms. A new study has found that more than 60% of hospital staff’s uniforms are colonized with potentially pathogenic bacteria. The study, which was published in the September issue of the American Journal of Infection Control (Wiener-Well Y, et al. 2011;39:555-559), suggests that physicians and nurses may be transferring pathogens that could cause clinically relevant infection.

Page 1 of 3
Results 1 - 10 of 28